Episodes 16-30 of 119
FDA D.I.S.C.O.: L-Glutamine for Sickle Cell Disease
FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer
FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer
FDA D.I.S.C.O.: First Tissue/Site Agnostic Cancer Treatment Approval
FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma
FDA D.I.S.C.O.: Niraparib in Ovarian Cancer
FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer
FDA Confirms Leg and Foot Amputation Risk with Diabetes Medicine Canagliflozin
Introducing FDA's Drug Information Soundcast in Clinical Oncology (DISCO)
The JAMA Report™
Study Examines Effectiveness of Steroid Medication for Sore Throat
FDA Restricts Use of Prescription Codeine and Tramadol Pain Medicines in Chil...
Behind the Black Box: The Dark Side of Big Pharma Research
Beyond the Data: Overcoming Barriers to Medication Adherence for Chronic Dise...
Lea Ann Chen, MD
Gary Lichtenstein, MD
Crohn's & Colitis Foundation Perspectives
Biologics for Inflammatory Bowel Disease: Maximizing Benefits, Avoiding Compl...
Overcoming Barriers to Medication Adherence for Chronic Diseases
Clinical Reflections®: Reflecting on Missed Opportunities in Nontuberculous Mycobacteria Lung Disease